In particular, breast cancer risk does not seem to be generally increased by truncating or missense RAD50 variants [8, 9, 10, 11], although certain substitutions such as the Finnish founder variant RAD50*c.687delT may confer some increased breast cancer risk [6, 7]. Here, RAD50 is linked to breast carcinoma.